Monday, March 01, 2010
Avastin Treatment Overview for Healthcare Professionals - Avastin
Genentech's website: note section on serious side effects
FAQ: ClinicalTrials.gov - What is "Expanded Access"?
Answer:
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial....cont'd
Abstract: A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer
Although miRNAs have been implicated as oncogenes and tumor suppressors in a variety of human cancers, functional roles for individual miRNAs have not been described in clear cell ovarian carcinoma..... We performed deep sequencing to comprehensively profile miRNA expression in 10 human clear cell ovarian cancer cell lines compared with normal ovarian surface epithelial cultures and discovered 54 miRNAs that were aberrantly expressed.....Our experiments have revealed strong candidate miRNAs and their target genes that may contribute to the pathogenesis of clear cell ovarian cancer, thereby highlighting alternative therapeutic strategies for the treatment of this deadly cancer.
Australia news item: Most women don't know ovarian cancer symptoms
Louise Bayne, Chief Executive of Ovacome said: "In the last 20 years, there has been a transformation in the way ovarian cancer is treated - but public awareness of the symptoms has not kept up with this medical progress.
"Women are becoming more aware of other common female cancers and how to spot them - but ovarian cancer has been left behind."
The
UK Cochrane Centre is pleased to announce that we will broadcast the
plenary sessions from the Annual Meeting of UK and Ireland-based
Contributors to The Cochrane Collaboration live on the internet on
Tuesday and Wednesday of this week (details of the speakers are below).
The broadcasts will be free to view at www.cochrane.tv. The site does not require a login or any special software. We will also make recordings of the sessions available later.
We
are doing this in an effort to improve access to the sessions and we
apologise in advance if technical problems mean that it does not work
well. However, please be assured that we will be working hard to
resolve any problems that arise during the broadcasts.
First plenary from 13.00 to 14.00 GMT on March 2 2010
Chair: Jane Noyes
Director of the Centre for Health-Related Research atBangor University
The importance of The Cochrane Collaboration.
Tony Jewell, Chief Medical Officer, Welsh Assembly Government
Sense about science
Tracey Brown, Managing Director, Sense About Science
Hunting for snarks: The challenge of getting evidence into guidelines
Fergus Macbeth, Director of the Centre for Clinical Practice, National Institute for Health and Clinical Excellence
Director of the Centre for Health-Related Research at
The importance of The Cochrane Collaboration.
Tony Jewell, Chief Medical Officer, Welsh Assembly Government
Sense about science
Tracey Brown, Managing Director, Sense About Science
Hunting for snarks: The challenge of getting evidence into guidelines
Fergus Macbeth, Director of the Centre for Clinical Practice, National Institute for Health and Clinical Excellence
Second plenary from 13.30 to 15.00 GMT on March 3 2010
Chair: Julian Higgins
Co-Editor, Cochrane Handbook for Systematic Reviews of Interventions
Addressing reporting bias
Jonathan Sterne, Department of Social Medicine, University of Bristol
Co-Convenor, Bias Methods Group
The risk of bias tool
Doug Altman, Director, Centre for Statistics in Medicine; Co-Convenor, Bias Methods Group
Summary of findings tables
Phil Wiffen, Operations and Training Director, UK Cochrane Centre
Including non-randomized studies
Barney Reeves, Bristol Heart Institute, University of Bristol; Co-Convenor, Non-randomised Studies Methods Group
Incorporating economics
Miranda Mugford, School of Medicine, Health Policy and Practice, University of East Anglia; Chair of Convenors, Campbell and Cochrane Economics Methods Group
The role of qualitative evidence
Jane Noyes, Noreen Edwards Chair in Nursing Research; Director of the Centre for Health-Related Research, Bangor University; Co-Convenor, Qualitative Methods Research Group
How can we improve the quality of reviews?
David Tovey, Editor in Chief, The Cochrane Library
Correspondence: Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management
Correspondence: Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies
refers to original article (abstract):
Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategiesfull access:Gynaecological oncology Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer
"This is a small, single institution, retrospective study. The limitations imposed by these attributes have to be borne in mind when interpreting or using the findings of this study."
full access: Surgical training in gastrointestinal procedures within a UK gynaecological oncology subspecialty programme
"Table 4 also includes comparison with the published literature of gynaecological oncologists performing colorectal procedures on women with gynaecological cancers and of colorectal surgeons performing colorectal procedures on women with primary colorectal problems........Previous publications from various countries, including the USA, Australia, Japan, France, Italy, South Africa, Singapore, China and Turkey, show similar rates of performance of gastrointestinal procedures in the management of gynaecological malignancies with similar complication rates."
Recovery Act Funding at NCI - NCI (30 new)
Note: see website for list
Clinical Trials Supported by Accelerating Clinical Trials of Novel Oncologic PathWays (ACTNOW) Initiative
ACTNOW is an early-phase clinical trial program designed to help shorten the time it takes to move new cancer treatments from the discovery phase, to drug development, and, ultimately, to approval and safe use by cancer patients.
The table below lists the ACTNOW trials by cancer type, and contains links to descriptions of the drugs being studied, the trial objectives, patient enrollment criteria, and locations where patients receive treatment. Investigators interested in collaborating on these trials can contact the Study Chair listed on the trial description.
Is the subject of this story going to kill you or cure you? - Gary Schwitzer's HealthNewsReview Blog
Note: see website for the link
Is the subject of this story going to kill you or cure you?
By Gary Schwitzer on February 26, 2010 9:20 AM
There's now a website that actually tracks The Daily Mail of London to categorize its stories as either "kill or cure" stories. The site quotes British physician-author Ben Goldacre: "The Daily Mail, as you know, is engaged in a philosophical project of mythic proportions: for many years now it has diligently been sifting through all the inanimate objects in the world, soberly dividing them into the ones which either cause - or cure - cancer."
Visitors to the site can vote on the stories.
BBC News - Gene test aid to cancer treatment
"Starting with 829 genes in breast cancer cells, the team whittled down the possibilities to six genes which had an impact on whether a drug worked."
full free access: Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma (repost from Jan 2010)
Note: also note reference materials included in this paper
Subscribe to:
Posts
(
Atom
)
Posts
